Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AV-1959D
- Development stage
- Phase 1
- Lead developer
- Institute for Molecular Medicine
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Electroporation
01
Overview
AV-1959D is a DNA-based epitope vaccine designed to induce an immune response against amyloid-beta (Aβ) for the prevention and treatment of Alzheimer's disease. The vaccine encodes three copies of the Aβ1–11 B cell epitope fused to the MultiTEP platform, which contains multiple universal foreign T helper epitopes recognized by diverse human MHC class II alleles. This design aims to stimulate robust anti-Aβ antibody production by activating both naïve and memory T helper cells while avoiding activation of potentially harmful autoreactive T cells. Delivered via electroporation, AV-1959D has demonstrated immunogenicity and safety in preclinical models (mice, rabbits, non-human primates), with no significant adverse neuropathological effects observed. The vaccine is currently being evaluated in Phase I clinical trials for early Alzheimer's disease[1][5][6][7].
- Other names
- AV 1959DAV1959DAV-1959DAbeta-DNA-vaccine
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on AV-1959D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AV-1959D.